Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China

Xiaoting Song; Bo Liu; Tingting Luan; Shuanglu Liao; Yen Tan; Chengyue Peng; Zuotao Zhao

doi:10.1111/all.15660

Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China

Allergy. 2023 Jun;78(6):1696-1699. doi: 10.1111/all.15660. Epub 2023 Feb 13.

Authors

Xiaoting Song^{1

2

3

4}, Bo Liu^{1

2

3

4}, Tingting Luan^{1

2

3

4

5}, Shuanglu Liao^{1

2

3

4}, Yen Tan^{1

2

3

4}, Chengyue Peng^{1

2

3

4

5}, Zuotao Zhao^{1

2

3

4}

Affiliations

¹ Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
² Beijing Key Laboratory of molecular Diagnosis on Dermatoses, Beijing, China.
³ National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
⁴ NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing, China.
⁵ Peking University School of Nursing, Beijing, China.

PMID: 36708064
DOI: 10.1111/all.15660

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / adverse effects
China / epidemiology
Dermatitis, Atopic* / drug therapy
Double-Blind Method
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal